Course: Iris Neovascularization After Vitreous Metastasis of a Cutaneous Melanoma
CME Credits: 1.00
Released: 2023-12-21
A 75-year-old man had a 1-year history of cutaneous melanoma and was undergoing immunotherapy with an inhibitor of programmed cell death protein 1. Although his systemic disease was in remission, the patient developed a vitreous metastasis in his left eye (confirmed by vitreous biopsy). During follow-up, he presented with neovascular glaucoma (intraocular pressure, 27 mm Hg) with iris and angle neovascularization (Figure, A), which have been associated with intravitreous metastatic cutaneous melanomas.1 An intracameral injection of repackaged (compounded) bevacizumab, 1.25 mg per 0.05 mL (Avastin [Genentech]), was performed. After 5 days, the iris neovascularization regressed, but amorphous material and tumor cells accumulated in the anterior chamber (Figure, B). Unfortunately, the patient also developed a rhegmatogenous retinal detachment (secondary to the previous biopsy) and after 3 months, the eye had to be enucleated. At the last follow-up, 23 months after iris neovascularization, the patient remains alive without melanoma recurrence, undergoing regular oncologic monitoring.
To identify the key insights or developments described in this article
View Full Course